While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for meds like Ozempic and Zepbound has decreased.

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

A person can get Zepbound through Medicare Part D or Part C plans with drug coverage to treat this condition ... you in making personal decisions about insurance, but it is not intended to ...

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...